Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Investing Activities (2020 - 2025)

Arcutis Biotherapeutics has reported Cash from Investing Activities over the past 6 years, most recently at -$34.2 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$34.2 million for Q4 2025, down 198.0% from a year ago — trailing twelve months through Dec 2025 was -$30.3 million (down 204.97% YoY), and the annual figure for FY2025 was -$30.3 million, down 204.97%.
  • Cash from Investing Activities for Q4 2025 was -$34.2 million at Arcutis Biotherapeutics, down from -$25.2 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for ARQT hit a ceiling of $107.8 million in Q1 2023 and a floor of -$197.3 million in Q3 2022.
  • Median Cash from Investing Activities over the past 5 years was $16.4 million (2022), compared with a mean of $782350.0.
  • Biggest five-year swings in Cash from Investing Activities: crashed 5783.15% in 2022 and later soared 604.39% in 2023.
  • Arcutis Biotherapeutics' Cash from Investing Activities stood at $23.5 million in 2021, then skyrocketed by 79.59% to $42.2 million in 2022, then crashed by 247.36% to -$62.2 million in 2023, then soared by 156.08% to $34.9 million in 2024, then crashed by 198.0% to -$34.2 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$34.2 million (Q4 2025), -$25.2 million (Q3 2025), and $17.4 million (Q2 2025) per Business Quant data.